MP19-04 QUALITY OF LIFE AFTER A UROLOGIC CANCER DIAGNOSIS

Abstract

You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality of Life and Shared Decision Making II (MP19)1 Sep 2021MP19-04 QUALITY OF LIFE AFTER A UROLOGIC CANCER DIAGNOSIS Ridwan Alam, Sunil Patel, Max Kates, Nirmish Singla, Mohamad Allaf, Trinity Bivalacqua, and Phillip Pierorazio Ridwan AlamRidwan Alam More articles by this author , Sunil PatelSunil Patel More articles by this author , Max KatesMax Kates More articles by this author , Nirmish SinglaNirmish Singla More articles by this author , Mohamad AllafMohamad Allaf More articles by this author , Trinity BivalacquaTrinity Bivalacqua More articles by this author , and Phillip PierorazioPhillip Pierorazio More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002004.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Quality of life (QOL) plays an important role in the care of patients with urologic malignancies, each of which is associated with a unique risk-benefit profile. We sought to compare the differential effects of a cancer diagnosis on quality of life across a number of urologic malignancies. METHODS: The Surveillance, Epidemiology, and End Results database was linked to the Medicare Health Outcomes Survey (SEER-MHOS) in this population-based cohort study. Patients were identified based on the diagnosis of a urologic malignancy and a complete QOL questionnaire, which is comprised of mental component summary (MCS) and physical component summary (PCS) scores. Six types of urologic cancers were examined: 1) bladder, 2) ureteral, 3) kidney, 4) prostate, 5) testicular, and 6) penile. Patients were classified based on whether the survey was taken before or after cancer diagnosis. Multivariable regressions were performed to examine the effect of a cancer diagnosis on QOL scores, after controlling for potential confounders. RESULTS: A total of 40,020 patients were included: cancer of the bladder in 7775, ureter in 580, kidney in 3197, prostate in 28,118, testicle in 148, and penis in 202. The diagnosis of cancer was significantly associated with a drop in MCS scores in all cancers except testicular (Figure). Those with ureteral cancer suffered the greatest drop in MCS scores (-3.76 points, p<0.001), even after adjustment (-3.75 points, p=0.007). The strength in association between MCS and diagnosis was the greatest for bladder cancer patients (-1.18 points, p<0.001). PCS scores also dropped significantly in all cancers except testicular (Figure), with the greatest drop seen in penile cancer patients (-6.64 points, p<0.001). After adjustment, however, this relationship was no longer significant (-3.95 points, p=0.08). Instead, bladder cancer patients demonstrated the greatest drop in physical health scores (-2.27 points, p<0.001). CONCLUSIONS: QOL is affected to varying degrees after the diagnosis of a urologic cancer based on the type of malignancy. Bladder cancer patients are at particularly high risk of mental and physical health decline after diagnosis when compared to other urologic cancer patients, possibly due to the significant lifestyle changes associated with this disease process. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e328-e328 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ridwan Alam More articles by this author Sunil Patel More articles by this author Max Kates More articles by this author Nirmish Singla More articles by this author Mohamad Allaf More articles by this author Trinity Bivalacqua More articles by this author Phillip Pierorazio More articles by this author Expand All Advertisement Loading ...